Darzalex Faspro 1800 mg Injection 1's

Darzalex Faspro 1800 mg Injection 1's belongs to the group of monoclonal antibodies (anti-cancer medicines) used to treat a type of blood cancer called multiple myeloma in adults 18 years or older. Multiple myeloma, also known as myeloma, is a type of bone marrow cancer that affects several areas of the body, such as the spine, skull, pelvis, and ribs.

Daratumumab, a monoclonal antibody, is present in Darzalex Faspro 1800 mg Injection 1's. Daratumumab is meant to bind to certain cancer cells in your body, either directly killing multiple myeloma cells and/or allowing your immune system to identify and destroy them.

Darzalex Faspro 1800 mg Injection 1's should be administered to patients only in a hospital setting under the supervision of a physician qualified by training and experience to administer cancer chemotherapeutic agents. Sometimes, you may experience common side effects, such as Chills, sore throat, cough, feeling sick (nausea), vomiting, itchy, runny or blocked nose, feeling short of breath or other breathing problems, chest discomfort, dizziness or light-headedness (hypotension), itching and wheezing. Most of these side effects do not require medical attention and will resolve gradually over time. However, you are advised to talk to your doctor if any of these side effects persist or worsen.

Before taking the Darzalex Faspro 1800 mg Injection 1's, inform your doctor about all your allergic or hypersensitivity reactions to medicines or food. Darzalex Faspro 1800 mg Injection 1's can cause fetal harm when administered to a pregnant woman. It is critical not to become pregnant or get pregnant while undergoing therapy and for several months afterwards. Before beginning treatment, discuss effective contraception with your healthcare professional. Inform them immediately if you or your partner becomes pregnant while undergoing therapy. Breastfeeding is usually not advised during this treatment since it is unknown whether this medication passes into breast milk. Alcohol should be avoided during treatment with this medicine. Drive only if alert, as the Darzalex Faspro 1800 mg Injection 1's may cause drowsiness or dizziness.

Daratumumab, a monoclonal antibody, is present in Darzalex Faspro 1800 mg Injection 1's. Monoclonal antibodies are proteins that recognize and bind to specific targets within the body. Daratumumab is a targeted monoclonal antibody meant to bind to certain cancer cells in your body that helps slow or stop the progression of multiple myeloma; it directly kills multiple myeloma cells and/or allows your immune system to identify and destroy them.

Before taking Darzalex Faspro 1800 mg Injection 1's, inform your doctor about your medical history and other medications you are currently taking to rule out any potential negative effects. Avoid taking Darzalex Faspro 1800 mg Injection 1's if you are pregnant or breastfeeding or allergic to any component present in Darzalex Faspro 1800 mg Injection 1's. Both women and men using this Darzalex Faspro 1800 mg Injection 1's should use birth control to avoid pregnancy. Inform your doctor if you have a history of low blood pressure; your doctor will closely monitor and manage it. If you are taking medication to help lower your blood pressure, you may need to reduce or discontinue it while taking Daratumumab.

• Monitoring of complete blood count while taking Darzalex Faspro 1800 mg Injection 1's is advised.
• Drink plenty of fluids to prevent urinary problems.
• If you are due to have any surgery, inform the doctor that you are taking Darzalex Faspro 1800 mg Injection 1's.
• Insomnia or difficulty sleeping at night is a common side effect of Daratumumab. This may be minimised by taking Daratumumab in the morning.
• Women who are being given Darzalex Faspro 1800 mg Injection 1's should use effective contraception during treatment and for three months after treatment.